Alto Neuroscience (ANRO) Liabilities and Shareholders Equity (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $276.3 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 60.7% year-over-year to $276.3 million; the trailing twelve-month figure through Mar 2026 stood at $765.8 million (up 3.71% YoY), and the FY2025 full-year result was $184.7 million, up 4.03% from the prior year.
• Liabilities and Shareholders Equity climbed to $276.3 million in Q1 2026, from $184.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $276.3 million in Q1 2026 to a low of $86.6 million in Q4 2023.
• A 4-year average of $180.1 million and a median of $181.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 104.95% in 2024 and declined 23.28% in 2025, its largest moves.
• Tracing ANRO's Liabilities and Shareholders Equity over 4 years: stood at $86.6 million in 2023, then surged by 104.95% to $177.5 million in 2024, then grew by 4.03% to $184.7 million in 2025, then soared by 49.58% to $276.3 million in 2026.
• Business Quant data shows ANRO's Liabilities and Shareholders Equity at $276.3 million in Q1 2026, $184.7 million in Q4 2025, and $147.0 million in Q3 2025.